Thubrikar Aortic Valve

Executive Summary

Thubrikar Aortic Valve is a clinical-stage medical device company developing the Optimum TAVI System, a transcatheter aortic valve designed to mimic the natural aortic valve's form and function for superior durability. Founded by Dr. Mano Thubrikar, a leading authority on aortic valve mechanics with over 30 years of research, the company aims to address the limitations of current transcatheter aortic valve replacements (TAVR), particularly in younger, low-risk patients where device longevity is critical. The Optimum TAVI System leverages a unique design that reduces stress on leaflets, potentially extending valve lifespan and reducing the need for reintervention. The company is poised to advance its clinical program, with several near-term milestones expected to drive value. As a private entity, Thubrikar Aortic Valve may seek strategic partnerships or additional financing to support pivotal trials and regulatory submissions. The market opportunity is substantial, given the growing prevalence of aortic stenosis and the trend toward expanding TAVR indications to younger patients. Successful clinical data demonstrating durability could differentiate the Optimum TAVI System from competitors and position the company as a key player in the cardiovascular device space.

Upcoming Catalysts (preview)

• Q4 2026Completion of feasibility study and initiation of pivotal trial50% success
• Q2 2027FDA IDE approval for pivotal study60% success
• TBDStrategic partnership or licensing agreement with major cardiovascular company30% success